VERI Investor Alert: HBSS Probes Claims Alleged Against Veritone, Inc. (VERI) in Pending Securities Class Action Regarding Alleged Accounting Irregularities

PR Newswire

SAN FRANCISCO, July 7, 2026 /PRNewswire/ — National shareholder rights firm Hagens Berman (HBSS) is actively investigating claims alleged against Veritone, Inc. (NASDAQ: VERI) and certain of its executives in a pending securities class action filed after the company admitted its previously issued financial statements were materially misstated.

Class Action


SUBMIT YOUR VERI LOSSES TO HBSS

The firm’s investigation focuses on the suit’s claims that Veritone and its management violated the securities laws by intentionally misleading investors regarding the company’s financial performance through improper accounting practices during the period from October 14, 2025, to April 14, 2026.                                  

Allegations of Improper Accounting and Revenue Inflation:

The securities class action follows a series of disclosures in early 2026 that resulted in significant declines in Veritone’s share price. The core allegations, which emerged in a recently filed complaint against the company, claim that Veritone failed to disclose that it:

  • Inaccurately recorded and/or misclassified certain revenue and costs. 
  • Overstated its revenue, assets, accounts receivable, royalties, and other comprehensive income. 
  • Maintained deficient internal controls over accounting and financial reporting. 
  • Provided investors with positive statements regarding its business, operations, and prospects that lacked a reasonable basis.

Key Disclosures and Market Impact

  • March 26, 2026: Veritone announced that it was “finalizing its accounting determination of certain revenue transactions,” causing shares to fall over 29% the following day.
  • April 1, 2026: The company delayed its annual report filing due to accounting determination issues regarding barter revenue, leading to another stock decline. 
  • April 14, 2026: Veritone formally disclosed that its unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2025, should no longer be relied upon, citing errors in software valuation and revenue misclassification, which drove the price of Veritone shares down further.

Hagens Berman’s Investigation

“Our investigation is focused on whether Veritone and its management intentionally misled investors about its financial performance using now-admitted improper accounting,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

Investor Rights and Court Deadlines

If you invested in Veritone securities during the Class Period (October 14, 2025 – April 14, 2026) and suffered financial losses, you may be eligible to serve as lead plaintiff in the ongoing litigation. The court-imposed deadline to move for appointment as lead plaintiff is July 20, 2026.

View our latest video summary of the allegations: youtu.be/dflmz_R1g64

Whistleblowers: Persons with non-public information regarding Veritone should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/veri-investor-alert-hbss-probes-claims-alleged-against-veritone-inc-veri-in-pending-securities-class-action-regarding-alleged-accounting-irregularities-302820068.html

SOURCE Hagens Berman Sobol Shapiro LLP

RBLX Investor Alert: HBSS Investigating Claims Against Roblox (RBLX) In Pending Securities Class Action Over Alleged Misleading Statements Regarding Age-Check Rollout Impact

PR Newswire

SAN FRANCISCO, July 7, 2026 /PRNewswire/ — National shareholder rights firm Hagens Berman is investigating claims alleged in a pending securities class action suit against Roblox Corporation (NYSE: RBLX) and its management following disclosures that the company’s age verification rollout caused significant, undisclosed friction to its user growth and platform engagement.

Class Action


SUBMIT YOUR RBLX LOSSES TO HBSS NOW

The firm’s investigation focuses on the suit’s claims that Defendants misled investors regarding the operational consequences of the safety-focused initiatives the company had purportedly implemented.

Allegations Concerning Age Verification and Growth:

The suit follows a sharp decline in Roblox’s share price on May 1, 2026, after the company reported its Q1 2026 financial results. The core allegations, which have emerged in recently filed complaint against the company, contend that Roblox failed to disclose that its age-check rollout:

  • Reduced Platform Engagement: The age verification features hindered on-platform communication, leading to a decline in user interaction.
  • Negatively Impacted Organic Growth: The friction caused by these features resulted in lower app store ratings and a corresponding reduction in organic user sign-ups.
  • Misrepresented Growth Potential: Throughout the class period (October 30, 2025 – April 30, 2026), Roblox characterized the rollout as a “gold standard” implementation while allegedly knowing it would lead to a significant slowdown in user growth.

Key Disclosures and Market Impact

  • April 30, 2026: Roblox revealed a steep deceleration in year-over-year and sequential DAU growth, slashed its 2026 revenue guidance and severely cut its 2026 bookings growth. The company blamed its dismal results on just 51% of Roblox global DAUs having age checked. The company further revealed that “as a result of age check […] we have seen a reduction in app store ratings, and we believe this may be contributing to a reduction in organic sign-ups that typically flow from app stores.” Roblox also said its lowered prospects are the result of “continued friction” resulting from the age-check rollout.
  • Market Correction: The news caused Roblox shares to fall $10.13, or approximately 18.33%, on May 1, 2026, erasing over $6.7 billion in market capitalization.

Hagens Berman’s Investigation

“We’re focused on when Roblox and its management knew of the adverse consequences of the age-check rollout and whether they intentionally misled investors about it,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

Investor Rights and Lead Plaintiff Deadline

Hagens Berman is currently evaluating the claims alleged in the suit brought on behalf of a putative class of investors who purchased Roblox securities between October 30, 2025, and April 30, 2026. If you suffered financial losses on RBLX during the class period, you are encouraged to contact our office to learn more about your legal rights and the ongoing class action litigation.  The court-imposed deadline to move for appointment as lead plaintiff is August 7, 2026.

If you’d like more information and answers to other frequently asked questions about the Roblox case and the firm’s investigation, read more.

Whistleblowers: Persons with non-public information regarding Roblox should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/rblx-investor-alert-hbss-investigating-claims-against-roblox-rblx-in-pending-securities-class-action-over-alleged-misleading-statements-regarding-age-check-rollout-impact-302820059.html

SOURCE Hagens Berman Sobol Shapiro LLP

Pinnacle West Sets Date for 2026 Second-Quarter Financial Results, Webcast/Conference Call

Pinnacle West Sets Date for 2026 Second-Quarter Financial Results, Webcast/Conference Call

PHOENIX–(BUSINESS WIRE)–
Pinnacle West Capital Corp. (NYSE: PNW) announced today that it plans to release its 2026 second-quarter financial results before U.S. financial markets open on Tuesday, Aug. 4, 2026.

That same day at noon ET (9 a.m. Arizona time), management will host a live webcast and conference call to discuss financial results and recent developments.

To access the live session:

  • Join the webcast at www.pinnaclewest.com/presentations for audio of the call and slides; or

  • Dial (888) 506-0062 or (973) 528-0011 for international callers and enter participant access code 293662.

To access the replay:

  • Visit www.pinnaclewest.com/presentations within 30 days for the webcast recording; or

  • An audio recording will be available by phone until 11:59 p.m. ET, Tuesday, Aug. 11, 2026, by calling (877) 481-4010 in the U.S. and Canada or (919) 882-2331 internationally and entering replay passcode 54218.

Pinnacle West Capital Corp., an energy holding company based in Phoenix, has consolidated assets of about $31 billion, about 6,200 megawatts of generating capacity and approximately 6,600 employees in Arizona and New Mexico. Through its principal subsidiary, Arizona Public Service, the company provides retail electricity service to about 1.5 million Arizona homes and businesses. For more information about Pinnacle West, visit the company’s website at pinnaclewest.com.

Media Contact: Alan Bunnell (602) 250-3376

Analyst Contact: Amanda Ho (602) 250-3334

Website: pinnaclewest.com

KEYWORDS: United States North America Arizona

INDUSTRY KEYWORDS: Utilities Energy

MEDIA:

Logo
Logo

51Talk Marks 15th Anniversary with Global Curriculum Upgrade to Enhance Children’s English Communication Skills

PR Newswire

SINGAPORE, July 7, 2026 /PRNewswire/ — 51Talk, a global live 1-on-1 online English learning platform for children, today announced a comprehensive global curriculum upgrade to celebrate its 15th anniversary. More than a product upgrade, this initiative reflects 51Talk’s enduring commitment to global education: empowering children to communicate confidently across cultures, connect with the world, and make their voices heard.

A student attends a live online 1-on-1 English lesson on the 51Talk app.

Founded in 2011, 51Talk now serves families across more than 50 countries and regions, with a strong presence across Southeast Asia, the Middle East, and East Asia. Through live 1-on-1 English lessons and structured learning pathways, the platform has consistently helped children develop speaking confidence through regular practice and immersive interaction.

An Integrated Curriculum Upgrade

Starting this July, 51Talk will roll out its new online English learning curriculum, Global Communicator. Built on academic excellence and real-world relevance, the upgraded curriculum delivers internationalized content, personalized learning pathways, and a highly interactive learning experience designed to develop confident global communicators.

The curriculum incorporates Oxford University Press-authorized course materials, adapted for young learners and aligned with internationally recognized English proficiency standards. An AI-powered adaptive learning system analyzes student performance and adjusts lesson difficulty in real time, enabling truly personalized learning. Powered by an advanced interactive engine, the curriculum simulates authentic real-life scenarios, helping students develop the confidence and skills to communicate naturally and effectively in English.

“Our goal has always been to help children apply their English communication skills confidently in everyday situations,” said Lucy Qu, Vice President of Academics at 51Talk. “This upgrade further enhances how we deliver interactive, responsive, and communication-focused learning.”

Real Voices: From Classroom to Global Stage

Since 2023, 51Talk has supported youth public speaking initiatives at international events such as the United Nations Climate Change Conference (COP), empowering students to voice their perspectives on real-world issues.

Le Bao Nhi from Vietnam, who was once hesitant to speak, found her voice through 51Talk lessons and ultimately spoke at COP30. “I used to be shy and afraid of making mistakes,” she shared. “Now, I’m proud to connect with people worldwide in English. We must believe that small hands can make a big difference.” Sheddi Alharthi from Saudi Arabia also experienced a remarkable transformation after speaking at COP30, noting, “Speaking English with confidence has opened up a much bigger world for me.”

One of 51Talk’s 5-Star teachers noted that confidence grows through consistent practice in a supportive learning environment, empowering students to express themselves freely in English. “Our mission goes beyond teaching English,” the teacher shared. “Through continuous guidance and companionship, we hope every child can speak English confidently in real-life situations.”

Looking Ahead to the Next Chapter

Standing at this 15-year milestone, 51Talk remains dedicated to enhancing its live 1-on-1 online English learning experience. Supported by passionate teachers and an AI-powered learning system, the platform will continue to help more children develop communication skills and the confidence to connect with the world. 51Talk looks forward to seeing more young learners find their voices and shine on the global stage.

To learn more, please visit: www.51talk.com

51Talk student representatives deliver speeches in English at the United Nations COP30.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/51talk-marks-15th-anniversary-with-global-curriculum-upgrade-to-enhance-childrens-english-communication-skills-302818215.html

SOURCE 51Talk

Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash

BURLINGTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) — Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics,” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 2,112,677 shares of common stock (or pre-funded warrants in lieu thereof), Series F warrants to purchase up to 2,112,677 shares of common stock and short-term Series G warrants to purchase up to 2,112,677 shares of common stock at a purchase price of $1.42 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. The Series F warrants and the Series G warrants will have an exercise price of $1.42 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants (the “Stockholder Approval Date”). The Series F warrants will expire five years from the later of (x) the Stockholder Approval Date or (y) the effective date of the registration statement covering the resale of the shares issuable upon exercise of the warrants (the “Effective Date”), and the Series G warrants will expire 18 months from the later of (x) the Stockholder Approval Date or (y) the Effective Date. The closing of the offering is expected to occur on or about July 9, 2026, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds from the offering are expected to be approximately $3.0 million, prior to deducting placement agent’s fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Series F warrants and the Series G warrants, if fully exercised on a cash basis, will be approximately $6.0 million. No assurance can be given that any of the warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the warrants. The Company intends to use the net proceeds from the offering to fund clinical trials, maintain and extend its patent portfolio and for working capital and other general corporate purposes.

The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the shares, warrants and the shares of common stock issuable thereunder may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with investors, the Company has agreed to file a resale registration statement covering the securities described above.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Bone Biologics

Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking a clinical study in Australia with select strategic partners that builds on the preclinical research of the NELL-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company’s current beliefs and expectations, and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors including, but not limited to, those related to: the completion of the offering; the satisfaction of customary closing conditions related to the offering; the intended use of proceeds therefrom; the receipt of stockholder approval; the effectiveness of the registration statement covering the resale of the shares of common stock underlying the warrants; the potential exercise of the warrants and potential proceeds therefrom. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to market and other conditions. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks described under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement, and Bone Biologics undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Contacts:
CORE IR
(212) 655-0924
[email protected]



Concorde International Group Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

SINGAPORE, July 08, 2026 (GLOBE NEWSWIRE) — Concorde International Group Ltd. (Nasdaq: YOOV) (the “Company”), an integrated provider of technology-enabled security solutions, today announced that the Company received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated July 1, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification.

Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

The Notification Letter does not impact the Company’s listing on The Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until December 28, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s ordinary shares must have a closing bid price of at least US$1.00 for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by December 28, 2026, the Company may be eligible for additional time to regain compliance or may face delisting.

The Company’s business operations are not affected by the receipt of the Notification Letter. The Company intends to monitor the closing bid price of its ordinary shares and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.

About Concorde International Group

Concorde International Group Ltd (Nasdaq: YOOV), established in 1997, is a business-model-driven provider of security solutions and services, supported by advanced integrated technology enabling cluster surveillance of properties and assets with 24/7 system availability and real-time response. The Group offers the i-Guarding suite of smart solutions, including the patented i-Facility Sprinter (IFS), a mobile platform operating on its proprietary Cluster® aggregation to deliver one-of-its kind innovative security and facility maintenance services. The IFS is protected by patents in more than 29 jurisdictions worldwide.

The Company further integrates its Artificial Intelligence-as-a-Service (AIaaS) capabilities, enabling organisations to deploy advanced AI-driven solutions without significant infrastructure investment. The company’s comprehensive offerings transform traditional security models to deliver enhanced operational performance, consistency, scalability, and cost-efficiency across multiple sectors.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement and annual report filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Investor Relations
Concorde International Group Ltd
Email: [email protected]



IperionX Announces Pricing of Public Offering of American Depositary Shares

SOUTH BOSTON, Va., July 07, 2026 (GLOBE NEWSWIRE) — IperionX Limited (“IperionX” or the “Company”) (Nasdaq:IPX; ASX:IPX) today announced the pricing of an underwritten public offering of 2,275,000 of its American Depositary Shares (“ADSs”), with each ADS representing 10 of its ordinary shares (“Public Offering”), at a price per ADS to the public of $21.98, for aggregate gross proceeds of approximately $50 million, before deducting underwriting discounts, commission and estimated offering expenses payable by the Company. The Public Offering was led by U.S. institutional investors and is expected to close on July 9, 2026, subject to customary closing conditions.

Proceeds from the Public Offering will be used to continue the commercialization and scale-up of certain of our titanium and metal alloy production technologies, including continued scale-up and expansion of the Company’s Titanium Manufacturing Campus in Virginia and associated titanium metal research and development activities, continued development of the Camden-Titan Project in Tennessee, and for general corporate purposes.

Cantor is acting as sole book-running manager for the Public Offering. Roth Capital Partners and B. Riley Securities are acting as co-managers for the Public Offering.

A shelf registration statement on Form F-3 (File No. 333-273519) was filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 28, 2023 and declared effective on August 9, 2023. The Public Offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus related to the Public Offering was filed with the SEC and is available on the SEC’s website at http://www.sec.gov and on the ASX’s website at http://www.asx.com.au. A final prospectus supplement related to the Public Offering will be filed with the SEC and made available on the SEC’s website at http://www.sec.gov and on the ASX’s website at http://www.asx.com.au. Copies of the final prospectus supplement, when available, and the accompanying prospectus relating to the Public Offering may be obtained from Cantor, Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, Email: [email protected].

The 22,750,000 ordinary shares that are to represent the ADSs will be issued using the Company’s placement capacity in accordance with Listing Rule 7.1.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities in the United States or in any other jurisdiction where such offer or sale is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as “anticipate”, “believe”, “expect”, “estimate”, “may”, “will”, “could”, “leading”, “intend”, “contemplate”, “shall” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements with respect to the anticipated closing date of the Public Offering and the anticipated use of proceeds from the Public Offering. Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements. Factors that may cause such differences include, but are not limited to: prevailing market conditions, whether or not the Company will be able to consummate the Public Offering; management’s broad discretion in the use of proceeds from any sale of ADSs; and risks related to the other matters described in the section titled “Risk Factors” in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

About IperionX

IperionX aims to be a leading American titanium metal and critical materials company – using patented titanium technologies to produce high performance titanium alloys, from titanium minerals or scrap titanium, at lower energy, cost and carbon emissions. IperionX’s award-winning patented technology portfolio enables high strength forged titanium alloy products at low cost, with class-leading sustainability and superior process energy efficiencies when compared to current industry methods such as the Kroll process. Using its technologies, IperionX has now transitioned to be a growing commercial producer of titanium metal products in the United States.

IperionX produces low-cost and high-quality angular and spherical titanium powder, which is used to produce near-net-shape and final titanium parts through powder metallurgy or additive manufacturing. These technologies provide IperionX with a sustainable competitive advantage and significant value uplift from upgrading raw titanium materials through to finished high-performance titanium products when compared to traditional titanium industry supply chains.

For further information, contact:

T: +1 980 237 8900
E: [email protected]



PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit

PR Newswire

NEW YORK, July 7, 2026 /PRNewswire/ —

Rosen Law Firm, P.A. Logo

Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 31, 2026.

So what: If you purchased Insulet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Insulet Corporation class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 31, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Insulet’s manufacturing controls and procedures were defective; (2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/podd-investors-have-opportunity-to-lead-insulet-corporation-securities-fraud-lawsuit-302820009.html

SOURCE THE ROSEN LAW FIRM, P. A.

BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit

PR Newswire

NEW YORK, July 7, 2026 /PRNewswire/ —

Rosen Law Firm Logo

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Badger Meter, Inc. (NYSE: BMI) between April 18, 2024 and April 16, 2026, inclusive (the “Class Period”), of the important August 3, 2026 lead plaintiff deadline.

So what: If you purchased Badger Meter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Badger Meter class action, go to https://rosenlegal.com/cases/badger-meter-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 3, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements concerning the drivers of Badger Meter’s “record” financial results, demand for Badger Meter’s products, and its prospects for continued growth. During the Class Period, defendants told investors that Badger Meter’s strong financial results reflected “ongoing favorable industry trends,” “secular growth drivers,” and “solid operating execution.” They likewise touted “strong” demand and said they were seeing “robust order pacing and a strong bid pipeline that positions us well for continued sales and earnings growth,” and that Badger Meter possessed a “long runway” for growth.

According to the lawsuit, these statements were materially false and misleading. In truth, Badger Meter’s financial results during the Class Period were at least partially attributable to Badger Meter’s practice of pulling-forward customer orders to recognize revenue early, which concealed weakening demand and deteriorating near-term order trends. This practice also depleted revenue otherwise available for future periods, ultimately causing the disappointing financial results Badger Meter later reported. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the Badger Meter class action, go to https://rosenlegal.com/cases/badger-meter-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bmi-investors-have-opportunity-to-lead-badger-meter-inc-securities-fraud-lawsuit-302820000.html

SOURCE THE ROSEN LAW FIRM, P. A.

WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit

PR Newswire

NEW YORK, July 7, 2026 /PRNewswire/ —

Rosen Law Firm Logo

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”), of the important August 3, 2026 lead plaintiff deadline.

So What: If you purchased GeneDx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the GeneDx class action, go to https://www.rosenlegal.com/cases/genedx-holdings-corp/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 3, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, the claims against defendants arise from their misrepresentations and omissions regarding GeneDx’s statements regarding the impact of Fabric on the overall business of GeneDx. Throughout the Class Period, GeneDx repeatedly made statements that would have caused the average investor to believe that the Fabric acquisition would improve GeneDx’s financials and create efficiencies between it and GeneDx’s core business. These statements include such statements such as: “There is room to run in terms of reducing COGS in the future by combining the best of capability between GeneDx and Fabric as we lean into the best possible algorithms to optimize dry lab processes.” These and similar statements made throughout the Class Period were false. In truth, defendants knew of, or recklessly disregarded, significant problems in Fabric’s viability that would negatively impact GeneDx’s overall business and operations. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the GeneDx class action, go to https://www.rosenlegal.com/cases/genedx-holdings-corp/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/wgs-investors-have-opportunity-to-lead-genedx-holdings-corp-securities-fraud-lawsuit-302819994.html

SOURCE THE ROSEN LAW FIRM, P. A.